HSPB1 and neurodegenerative disease: By activating HSPB1 expression to reduce aggregation, ROS and cytotoxicity in ΔK280 TauRD‐DsRed‐expressing cells (Figure 1), LM‐031 could be a promising disease‐modifying compound for the treatment of AD and other oxidative stress‐related neurodegenerative diseases.